Watson Pharmaceuticals Inc. July 11 announced that its subsidiary, Watson Laboratories Inc., has received approval from the Food and Drug Administration for its generic version of G.D. Searle’s Arthrotec (diclofenac sodium and misoprostol delayed-release tablets).
Arthrotec is indicated for treating the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nonsteroidal anti-inflammatory drug (NSAID)-induced gastric and duodenal ulcers and their complications, the Parsippany, N.J.-based company said.
Watson said it plans to launch the product in the fourth quarter of 2012.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.